By Dr. MercolaHuman papillomavirus (HPV) vaccines, marketed under the brand names Gardasil and Cervarix, are among the most controversial vaccinations offered in the U.S. — and the controversy, it appears, is only slated to get worse. Gardasil vaccine, manufactured by Merck, was fast-tracked to the U.S. market in 2006, without adequate evidence for safety and effectiveness in children. It was only studied in fewer than 1200 girls under 16 years old, who were followed up for about two years, before it was licensed by the Food and Drug Administration (FDA).1 The vaccine was originally touted as an anti-cervical cancer vaccine that should be given to all girls and women aged 9 to 26 years old, despite the fact it was rushed to licensure without first proving that it actually prevented cervical cancer, especially when given to pre-adolescent girls.2 Within five years, U.S. public health officials broadened HPV vaccine recommendations to include all pre-adolescent boys as well, in order
http://articles.mercola.com/sites/articles/archive/2017/02/28/hpv-vaccine-tested-on-infants.aspx
No comments:
Post a Comment